AXDX Stock Overview An in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Accelerate Diagnostics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Accelerate Diagnostics Historical stock prices Current Share Price US$1.16 52 Week High US$4.35 52 Week Low US$0.73 Beta 0.55 1 Month Change -29.27% 3 Month Change -24.18% 1 Year Change -73.21% 3 Year Change -97.68% 5 Year Change -99.30% Change since IPO -27.50%
Recent News & Updates
Accelerate Diagnostics, Inc. Announces FDA Clearance of its Accelerate Arc™? System Oct 01
Accelerate Diagnostics, Inc. Announces Successful Completion of Its Wave Pre-Clinical Trial Aug 09
Accelerate Diagnostics, Inc. to Report Q1, 2024 Results on May 08, 2024 May 03
Accelerate Diagnostics, Inc. Receives Written Notice from the Listing Qualifications Staff of Nasdaq May 01
Accelerate Diagnostics, Inc., Annual General Meeting, May 07, 2024 Apr 12
Accelerate Diagnostics, Inc. Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC Mar 06 See more updates
Accelerate Diagnostics, Inc. Announces FDA Clearance of its Accelerate Arc™? System Oct 01
Accelerate Diagnostics, Inc. Announces Successful Completion of Its Wave Pre-Clinical Trial Aug 09
Accelerate Diagnostics, Inc. to Report Q1, 2024 Results on May 08, 2024 May 03
Accelerate Diagnostics, Inc. Receives Written Notice from the Listing Qualifications Staff of Nasdaq May 01
Accelerate Diagnostics, Inc., Annual General Meeting, May 07, 2024 Apr 12
Accelerate Diagnostics, Inc. Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC Mar 06 Accelerate Diagnostics, Inc. announced that it expects to receive $4.749996 million in funding from Jack W. Schuler Living Trust Jan 25
Accelerate Diagnostics, Inc. has completed a Composite Units Offering. Jan 20
Accelerate Diagnostics Announces 1-For-10 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of $1.00 Per Share Required to Maintain Continued Listing on the Nasdaq Capital Market Jul 11
First quarter 2023 earnings: EPS and revenues miss analyst expectations May 12
Consensus EPS estimates fall by 15% Apr 25
Market Participants Recognise Accelerate Diagnostics, Inc.'s (NASDAQ:AXDX) Revenues Pushing Shares 38% Higher Apr 17
Full year 2022 earnings: Revenues and EPS in line with analyst expectations Apr 06
CEO, President & Director exercised options and sold US$73k worth of stock Mar 14
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Mar 06
Insufficient new directors Mar 01
Accelerate Diagnostics Receives A Deficiency Letter from Nasdaq Regarding Minimum Bid Price Requirement Jan 12
Accelerate Diagnostics Submits 510(K) Application to FDA for Gram-Negative Menu Expansion and Breakpoint Updates for the Accelerate Phenotest(R) BC Kit Dec 20
Accelerate Diagnostics, Inc. Announces Resignation of Ron Price as Chief Commercial Officer Dec 16
Consensus forecasts updated Nov 21
Price target decreased to US$2.00 Nov 16
Accelerate Diagnostics, Inc. Provides Earnings Guidance for the Year 2022 Nov 15
Insider recently bought US$80k worth of stock Aug 31
Accelerate Diagnostics spikes as Chief Technology Officer raises stake Aug 30
Consensus revenue estimates increase by 10% Aug 22
Need To Know: Analysts Are Much More Bullish On Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Aug 20 Accelerate Diagnostics, Inc. has completed a Follow-on Equity Offering in the amount of $35 million. Aug 20
Second quarter 2022 earnings: EPS and revenues exceed analyst expectations Aug 16
Accelerate Diagnostics jumps 14% after beating Q2 estimates Aug 15
CEO, President & Director exercised options and sold US$26k worth of stock Jun 27
Consensus forecasts updated May 23
Accelerate Diagnostics Announces Commercialization of its Accelerate Arc System Having Completed IVD Registration with FDA May 18
First quarter 2022 earnings: EPS exceeds analyst expectations May 17
CEO, President & Director exercised options and sold US$82k worth of stock Apr 29
Price target decreased to US$5.00 Apr 27
Accelerate Diagnostics, Inc., Annual General Meeting, May 12, 2022 Apr 08
Accelerate Diagnostics, Inc. Announces Launch of Accelerate Arc™ Module and BC Kit Mar 29
Need To Know: The Consensus Just Cut Its Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Estimates For 2022 Mar 15
Consensus revenue estimates fall by 14% Mar 15
Full year 2021 earnings: EPS exceeds analyst expectations Mar 09
Accelerate Diagnostics, Inc. Elects Wayne C. Burris as Member of the Board Feb 04
Insider recently bought US$66k worth of stock Feb 03
Independent Director recently bought US$524k worth of stock Jan 21
Independent Director recently bought US$196k worth of stock Jan 16
Accelerate Diagnostics, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2021 Jan 14
Independent Director recently bought US$277k worth of stock Jan 07
Accelerate Diagnostics And T2 Biosystems: Financial Woes Set To Continue In 2022 Jan 04
Independent Director recently bought US$369k worth of stock Dec 24
Independent Director recently bought US$248k worth of stock Nov 30
Independent Director recently bought US$606k worth of stock Nov 26
Accelerate Diagnostics, Inc. Announces New Accelerate Pheno System Multi-Center Study Published in Clinical Infectious Diseases Nov 24
Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.33 loss in 3Q 2020) Nov 10
Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.33 loss in 3Q 2020) Nov 10
Accelerate Diagnostics, Inc. announced that it has received $1.55 million in funding Oct 01
Independent Director recently bought US$150k worth of stock Sep 28
Price target decreased to US$11.00 Sep 24
Accelerate Diagnostics: An Investment Assessment Sep 07
Second quarter 2021 earnings released: US$0.35 loss per share (vs US$0.35 loss in 2Q 2020) Aug 12
Consensus forecasts updated Aug 07
Accelerate Diagnostics, Inc. to present New Accelerate Pheno® Landmark Study Validates Important Clinical Benefits at ECCMID 2021 Jul 01
CEO, President & Director exercised options and sold US$186k worth of stock Jun 25
Key Executive exercised options and sold US$56k worth of stock May 16
Price target decreased to US$11.00 May 11
First quarter 2021 earnings released: US$0.41 loss per share (vs US$0.39 loss in 1Q 2020) May 09
Accelerate Diagnostics, Inc. Announces Roland D. Diggelmann Decision Not to Stand for Re-Election to Its Board Mar 21
Analysts lower revenue estimates to US$16.5m Mar 02
Earnings beat expectations, revenue disappoints Feb 25
Full year 2020 earnings released: US$1.40 loss per share (vs US$1.55 loss in FY 2019) Feb 25
Should You Take Comfort From Insider Transactions At Accelerate Diagnostics, Inc. (NASDAQ:AXDX)? Feb 20
Key Executive exercised options and sold US$701k worth of stock Jan 29
New 90-day high: US$12.96 Jan 26
Price target lowered to US$12.33 Jan 16
Accelerate Diagnostics foresees Q4 and FY2020 revenue below consensus Jan 12
Reflecting on Accelerate Diagnostics' (NASDAQ:AXDX) Share Price Returns Over The Last Three Years Dec 29
New 90-day low: US$7.04 Dec 10
Price target lowered to US$14.33 Dec 06
Key Executive exercised options and sold US$256k worth of stock Nov 13
New 90-day low: US$8.87 Nov 10
Revenue beats expectations Nov 08
Third quarter 2020 earnings released: US$0.33 loss per share Nov 08
New 90-day low: US$9.88 Oct 22
Accelerate Diagnostics, Inc. Announces New FDA Clearance for Accelerate PhenoTest® Improvements Sep 17
Earnings released Aug 08
Price target raised to US$15.33 Aug 08
New 90-day high - US$18.04 Jul 16 Shareholder Returns AXDX US Medical Equipment US Market 7D -3.3% -1.2% -2.7% 1Y -73.2% 10.0% 23.4%
See full shareholder returns
Return vs Market: AXDX underperformed the US Market which returned 23.4% over the past year.
Price Volatility Is AXDX's price volatile compared to industry and market? AXDX volatility AXDX Average Weekly Movement 9.5% Medical Equipment Industry Average Movement 7.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.9% 10% least volatile stocks in US Market 3.2%
Stable Share Price: AXDX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AXDX's weekly volatility (10%) has been stable over the past year.
About the Company Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk.
Show more Accelerate Diagnostics, Inc. Fundamentals Summary How do Accelerate Diagnostics's earnings and revenue compare to its market cap? AXDX fundamental statistics Market cap US$29.05m Earnings (TTM ) -US$53.45m Revenue (TTM ) US$11.91m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) AXDX income statement (TTM ) Revenue US$11.91m Cost of Revenue US$9.02m Gross Profit US$2.89m Other Expenses US$56.34m Earnings -US$53.45m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -2.13 Gross Margin 24.25% Net Profit Margin -448.85% Debt/Equity Ratio -119.6%
How did AXDX perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 15:58 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Accelerate Diagnostics, Inc. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Sean Lavin BTIG Garrett Nelson CFRA Equity Research Alexander Nowak Craig-Hallum Capital Group LLC
Show 3 more analysts 
